Background
Acute liver failure (ALF) is a potentially lethal clinical syndrome with a high mortality rate. Nonetheless, immediate intensive care, specific therapies and liver transplantation (LTx) have improved the prognosis of ALF patients significantly [
1‐
3]. According to the European Liver Transplant registry, approximately nine percent of LTx were related to ALF [
4]. King’s college (KCC) and Clichy criteria are etiology specific, prognosis predicting allocation tools to warrant timely transplantation and fair organ distribution [
5,
6]. However, their accuracy to reliable predict patients’ individual prognosis and to discriminate those patients who will survive without LTx remains a major challenge [
7,
8].
The model of end-stage liver disease (MELD), initially established to predict survival following transjugular intrahepatic portosystemic shunt (TIPS) procedure and later as an allocation tool for patients with cirrhosis, has been implied as a prognostic tool in ALF and was proven to be superior to the KCC and Clichy criteria [
9‐
11]. Recently, various modifications of the MELD have been introduced and improved accuracy in both, chronic liver failure and ALF [
12,
13]. Since hepatic encephalopathy (HE) is associated with a fulminant course of ALF and a decrease in extracellular fluid osmolality is associated with an increase in brain swelling, factors that modulate fluid osmolality were taken into account as prognostic markers [
14,
15]. Patients with serum sodium between 145 and 150 mmol/l are known to have fewer episodes of intracranial hypertension and consequently a higher risk to develop brain edema. Thus, hyponatremia might worsen the prognosis in ALF [
16]. As hyponatremia is associated with poor prognosis in cirrhosis, inclusion of serum sodium (Na) into the MELD was found to improve its predictive value in chronic liver diseases [
13,
17]. Two sodium containing MELD modifications, “UKELD” and “MELD-Na”, were proposed to enhance its prognostic ability in chronic liver failure [
18,
19]. A potential predictive value of these modifications in ALF has not been evaluated yet.
The aim of this study was to determine whether inclusion of serum sodium into the MELD score improves its predictive value in ALF, compared to established criteria. By evaluating these tools in a large prospective single-center study with ALF patients, we demonstrate that the sodium based MELD modifications do not improve the prognostic value of the standard MELD formula.
Methods
Patients and ethical considerations
The study was carried out according to the Declaration of Helsinki and the guidelines of the International Conference for Harmonization for Good Clinical Practice, it was approved by the local Ethics Committee of the University Hospital Essen (Institutional Review Board). In a prospective monocenter study (11/2006–12/2010), we recruited 108 consecutive ALF patients (64% females / 36% males), who met the criteria defined by the “Acute Liver Failure Study Group Germany” [
20]. In brief, ALF was diagnosed by significant liver dysfunction with pathologically increased laboratory parameters (bilirubin, AST, ALT, AP, γ-GT) and an international normalized ratio (INR) of >1.5 with the concomitant presence of any degree of encephalopathy. Reference values for normal ranges are presented in Table
1. A pathological increase was defined as any value above these ranges. Other causes of liver dysfunction were excluded, such as acute-on-chronic liver failure or pre-existing cirrhosis. All patients had presented within four weeks of disease onset without pre-existing liver disease. Upon admission, clinical data were collected. Outcome (spontaneous recovery, SR; non-spontaneous recovery, NSR: comprising transplantation or death) was defined by the status after 4 weeks post admission.
Table 1
Patient’s general characteristics and laboratory parameter by outcome
Gender female (%)
| | 38 (58%) | 31 (72%) | 17 (71%) | 14 (73%) | |
Age**
| | 41 (64) | 49 (61) | 41.5 (48) | 56 (54) | p<0.05 | p<0.05 | n.s. | p<0.05 |
BMI (kg/m
2
) **
| | 23.37 (30.59) | 26.64 (46.83) | 25.91 (28.54) | 27.7 (42.82) | n.s. | n.s. | n.s. | n.s. |
PLATELETS [/nl]**
| 140-380 | 181 (350) | 165 (450) | 176.5 (450) | 130 (325) | n.s. | n.s. | n.s. | n.s. |
GGT [U/l]**
| <55 | 113 (1102) | 154 (1938) | 154 (720) | 158 (1938) | n.s. | n.s. | n.s. | n.s. |
ALP [U/l]**
| 25-124 | 151 (3024) | 183 (670) | 173 (450) | 214 (571) | n.s. | p<0.05 | n.s. | n.s. |
AST [U/l]**
| <50 | 2329 (18650) | 1081 (15388) | 837 (4642) | 2342 (15388) | n.s. | n.s. | p<0.05 | n.s. |
ALT [U/l]**
| <50 | 2288 (12955) | 1092 (7954) | 946.5 (7177) | 1682 (7835) | p<0.05 | n.s. | p<0.05 | n.s. |
INR**
| 0.89-1.11 | 1.77 (2.96) | 3.35 (8.36) | 3.64 (7.88) | 2.88 (8.17) | p<0.05. | p<0.05 | p<0.05 | n.s. |
Direct bilirubin [mg/dl]**
| <0.2 | 5.8 (28.7) | 13.8 (30) | 18.25 (28) | 9.3 (24.4) | p<0.05 | n.s. | p<0.05 | p<0.05 |
Total bilirubin [mg/dl]**
| 0.3-1.2 | 11.4 (40.5) | 20.2 (43.1) | 21.85 (37.7) | 15.4 (38.9) | p<0.05 | n.s. | p<0.05 | p<0.05 |
Creatinine [mg/dl]**
| 0.6-1.3 | 0.99 (5.09) | 1.81 (4.43) | 1.385 (4.43) | 2.5 (3.87) | p<0.05 | p<0.05 | p<0.05 | p<0.05 |
Sodium [mmol/l]**
| 136-145 | 138 (24) | 138 (27) | 137.5 (23) | 139 (27) | n.s. | n.s. | p<0.05 | n.s. |
MELD*
| | 23.55 ± 0.66 | 36.37 ± 0.68 | 36.33 ± 0.8638 | 36.42 ± 1.12 | p<0.05 | p<0.05 | p<0.05 | n.s. |
UKELD*
| | 58.39 ± 0.57 | 65.12 ± 0.73 | 66.29 ± 0.8666 | 63.47 ± 1.20 | p<0.05 | p<0.05 | p<0.05 | n.s. |
MELD-Na*
| | 24.5 ± 0.65 | 36.49 ± 0.65 | 36.67 ± 0.81 | 36.24 ± 1.1 | p<0.05 | p<0.05 | p<0.05 | n.s. |
Assessment of prognosis
Serum sodium, KCC, MELD, UKELD and MELD-Na were assessed upon admission. Parameters were correlated with the outcome at 4 weeks after admission. In order to calculate the individual MELD score we used the formula as published by Kamath
et al.[
21]. If the bilirubin and creatinine values were below 1.0 mg/dl they were set to 1.0 mg/dl. If the creatinine was above 4.0 mg/dl or the patients underwent dialysis during two weeks before assessment, the creatinine value was adjusted to 4.0 mg/dl. In order to calculate the individual MELD-Na score we used the formula as published by Ruf
et al.[
17]. If the sodium values were below 125 mmol/l they were set to 125 mmol/l, if the values were above 140 mmol/l they were adjusted to 140 mmol/l. In order to calculate the individual UKELD score we used the formula as published by Barber
et al.[
19]. The KCC were evaluated following published criteria. Differentiation between acetaminophen induced ALF and non-acetaminophen induced ALF have been made, as previously published [
22]. Detailed formulas of the utilized scores are given in Table
2.
Table 2
Model of end-stage liver disease (MELD) formula and sodium dependent modifications
Score
|
Formula
|
MELD |
|
MELDNa |
MELDNa = MELD − Na − [0.025 × MELD × (140 − Na)] + 140 |
UKELD |
|
Statistics
Differences between parameters were evaluated by one-way Analysis of Variance, repeated-measure Analysis of Variance, or paired Student’s t-test and t-test for independent samples t-test. For MELD and modified MELD statistics the Mann–Whitney test was used. For categorical variables, frequencies and percentages were estimated. χ2 or Fisher’s exact tests were used for categorical factors. ROC calculations were undertaken where applicable. Screening, optimal, and diagnostic cutoff values were calculated, and the optimal cutoff, including specificity and sensitivity as well as the AUC are shown in boxes included in the ROC plots. A p < 0.05 was considered statistically significant. All values are given as means ± standard error of means. Analyses were performed with SPSS 19.0.1, version 2008 (SPSS, Chicago, IL, USA).
Discussion and conclusion
To our knowledge, this is the first study to evaluate a potential predictive role for serum sodium based MELD modifications in the clinical setting of ALF in a large prospective cohort. Compared to the individual MELD parameters and in contrast to patients with chronic liver disease or post-transplant outcomes for acute liver failure [
23], we could not find a clear association between serum sodium levels and clinical outcome in ALF which is in line with recent studies [
24]. Accordingly, the serum sodium based MELD modifications MELD-Na and UKELD failed to improve the predictive value of the MELD in ALF patients. However, in our cohort the classic MELD as well as MELD-Na was superior to KCC in predicting outcome of ALF patients. Interestingly, hypernatremia was associated with lethal outcome in our ALF cohort. In contrast in chronic liver disease hyponatremia is associated with a worse outcome even for mid to long term survival [
25], the rational for utilizing UKELD and MELD-Na in cirrhosis.
Several studies have demonstrated a good specificity for KCC in ALF, however, the sensitivity to predict lethal outcome was modest in the vast majority of studies, especially in non-acetaminophen induced ALF [
2,
6,
26]. Here, we found a fairly good specificity for KCC to predict NSR and as previously published only a modest sensitivity. Recent studies identified MELD as a prognostic tool with better sensitivity compared to KCC [
21,
27]. Specifically, in patients with non-acetaminophen induced ALF, MELD was superior to KCC in predicting outcome [
9]. This is in line with our findings, which show a better performance of MELD and MELD-Na compared to KCC in non-acetaminophen ALF.
MELD was primarily introduced as a prognostic tool for survival of patients with cirrhosis and portal hypertension following TIPS procedure [
28]. Later, it was found to be useful in organ allocation for patients with chronic liver disease awaiting liver transplant and is therefore widely used in Western societies [
21]. As hyponatremia is a common clinical problem in patients with end stage liver disease, especially in those individuals with portal hypertension, ascites and hepatorenal syndrome, sodium based modifications of the MELD have been introduced. In the UK, the UKELD is utilized instead of the MELD for organ allocation [
19]. Murphy
et al. identified hyponatremia as an independent risk factor for brain edema, a fatal complication of ALF [
16,
29]. Furthermore hyponatremia has been investigated extensively in the management of traumatic cerebral edema [
30,
31]
In our study we could not find an advantage of sodium based MELD modifications, compared to MELD or KCC in ALF. This is most likely due to the absence of ascites or hepatorenal syndrome in ALF, both common co-morbidities of cirrhosis [
32,
33]. In our cohort, we did not find a difference in sodium levels between SR and NSR. Although Murphy
et al. showed that patients with serum sodium between 145 and 150 mmol/l had fewer episodes of intracranial hypertension. There has been no difference in outcome [
16]. Taken together we confirm previous publications, establishing MELD as a powerful prognostic tool for non-acetaminophen induced ALF patients.
Furthermore, our data revealed a crucial problem with the assessment of any prognostic factor. We found significant differences in its predictive value between the MELD at the time of admission and at the time-point of its biggest dimension. The maximum MELD performed best in predicting outcome in ALF, underlining the need for continuous clinical assessment of patients with ALF, given the heterogeneity and dynamic of this disease. However, this also shows the need for novel prognostic models and surrogate parameters for the degree of liver injury and disease progression [
34]. While other possible MELD modifications might improve its accuracy in the future [
12], sodium based MELD modifications are of little prognostic value in the clinical setting of ALF. Remien et al., in contrast to other modifications of the KCC and MELD-Score, developed the MALD score which is novel as it builds upon the KCC by utilizing an understanding of the dynamics of hepatocyte damage following APAP overdose in the form of a dynamic mathematical model [
35]. As ALF is a devasting clinical condition, it is worth it to evaluate new prognostic tools to improve outcome in this patients.
Competing interests
The authors declare that they have no competing interest.
Authors’ contributions
PM participated in the study design, collected patient material, performed statistical analyses and drafted the manuscript. LPB collected patient material and revised the manuscript for important intellectual content. FT participated in the study design and revised the manuscript for important intellectual content. JPS performed statistical analyses and revised the manuscript for important intellectual content. MS performed detection of various serum parameters. JK collected patient material. CJ participated in the study design and coordination and collected patient material. AP participated in study coordination and collected patient material. FHS participated in study coordination and collected patient material. CT participated in the study design and revised the manuscript for important intellectual content. GG participated in study coordination and revised the manuscript for important intellectual content. AC conceived of the study, and participated in its design and coordination and revised the manuscript for important intellectual content. All authors read and approved the final manuscript.